Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Latest News

Modern Medical Technologies | Image credit: Prostock-studio - stock.adobe.com
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML

August 16th 2025

Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.

Blast cells AML | image credit: Nun22 - stock.adobe.com
Long-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML

August 11th 2025

Stethoscope with health icons next to a white piggy bank | Image credit: Kiattisak - stock.adobe.com
Upfront HSCT More Cost-Effective for Patients With AML in Remission

July 31st 2025

Gloved hands holding ALL blocks | Image credit: Sviatlana - stock.adobe.com
Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

July 30th 2025

3D illustration showing abundant lymphoblasts in blood | Image credit: Dr_Microbe - stock.adobe.com
Obe-Cel Is Effective Irrespective of Age in Relapsed/Refractory B-ALL

July 14th 2025

More News

Research graphic | Image Credit: © marikova-stock.adobe.com
September 20th 2024

Multidisciplinary Prehabilitation to Boost Outcomes in AML, MDS for Stem Cell Transplant

Kimberly Rath, PharmD
A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) offered an allogenic hematopoietic stem cell transplantation.
Acute myeloid leukemia | Image: St Jude Children's Research Center
September 19th 2024

Institute for Value-Based Medicine®: Speakers Use AML Studies to Illustrate Effects of Disparities, Neighborhood Stress on Outcomes

Kyle Munz
Coverage from the Institute for Value-Based Medicine session at Ohio State University. This article will appear in the October issue of Evidence-Based Oncology.
Risk stratification in AML could benefit from mutational scoring | image credit: faraktinov - stock.adobe.com
September 17th 2024

Mutational Score May Improve Risk Stratification of Certain Patients With AML

AJMC Contributor
The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption of a mutation score that accounts for certain gene mutations.
AML | Image Credit: © Dzmitry - stock.adobe.com
September 9th 2024

Key Biomarker Monitoring Improves Outcomes in ASCT Recipients With AML, MDS

Karen Jacobson-Sive
Donor lymphocyte infusion, both alone and in combination with azacitidine, restored CD34 levels in two-thirds of patients with a baseline CD34 donor chimerism of less than 80%.
Enhanced image of leukemia | Image Credit: © freshidea - stock.adobe.com
September 6th 2024

Two Leukemia Stem Cell Subtypes Identified

Karen Jacobson-Sive
Researchers have discovered 2 leukemia stem cell subtypes with distinct epigenetic and transcriptional signatures.
Immunology word cloud | image credit: ibreakstock - stock.adobe.com
August 27th 2024

Researchers Identify Potential IO Targets in AML Through Surfaceome Analysis

AJMC Contributor
By analyzing the surface proteome of a wide-ranging sample of acute myeloid leukemia (AML) specimens, researchers identified potential antigens and primitive cell markers representative of AML supgroups.
AML cells | image credit: LASZLO - stock.adobe.com
August 17th 2024

AML Treatment Has Shifted Toward More Personalized Approach

AJMC Contributor
Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease.
Maria Amaya, MD, PhD
August 16th 2024

Real-World Outcomes Not Always Reflected in Clinical Trials: Dr Maria Amaya

Kyle Munz
Maria Amaya, MD, PhD, University of Colorado School of Medicine, explores discrepancies between real-world data and clinical trial outcomes, as well as her experience ensuring the reliability of real-world analysis.
ALL cancer cells in blood flow | Image Credit: © Laszlo - stock.adobe.com
August 15th 2024

Spontaneous Remission in Childhood Cancer Rare but Fleeting

Jared Kaltwasser
A case report suggests vigilance is required even when cancers like acute lymphoblastic leukemia appear to go into remission without explanation.
doc comforting patient | Image Credit: Seventyfour-stock.adobe.com
August 3rd 2024

Blinatumomab Boosts Survival in MRD-Negative BCP-ALL

Jared Kaltwasser
Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.
awareness of hematologic disorders | Image Credit: Orawan-stock.adobe.com
July 30th 2024

ActivinA Helps B-ALL Cells by Inducing Extracellular Vesicles

Jared Kaltwasser
A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).
pregnant woman who is too hot| Image Credit: Studio Romantic-stock.adobe.com
July 27th 2024

High Ambient Temperatures in Pregnancy Related to Childhood Leukemia Risk

Gayle Turim Dickstein
When the mercury outside ascends too high early in pregnancy, the risk of pediatric acute lymphoblastic leukemia may rise as well; results also show greater impacts on Latino populations.
acute leukemia | Image Credit: GoodIdeas-stock.adobe.com
July 22nd 2024

New Study Highlights Venetoclax Combo Efficacy in ALL

Kimberly Rath, PharmD
This new study evaluates the efficacy of monotherapies and venetoclax combination therapies in different T-cell acute lymphoblastic leukemia (ALL) cell lines.
AML cells | Image credit: Laszlo - stock.adobe.com
July 15th 2024

CPX-351 Effective in AML, Possibly With Reduced Cardiotoxicity vs Standard Anthracyclines

Karen Jacobson-Sive
Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity.
concept of a genetic mutation | Image Credit: © lucadp - stock.adobe.com
July 4th 2024

Certain Low-Prevalence Mutations May Be Strong Drivers in Pediatric ALL

AJMC Contributor
The researchers noted that most genomic analyses have traditionally focused on commonly mutated genes, which can pinpoint mutations occurring most frequently but does not account for the extent to which these mutations impact cancer cell survival and proliferation.
Survey graphic | Image Credit: Tierney-stock.adobe.com
July 1st 2024

In Acute Leukemia, Chance of Response Is Patient’s Top Concern

Jared Kaltwasser
Quality of life was also a top concern among patients when asked about their priorities if they experienced relapse or were refractory to therapy.
AML acronym | Image Credit: Natalya-stock.adobe.com
June 28th 2024

Review of Posttransplant Strategies for AML Relapse Prevention

Kimberly Rath, PharmD
Researchers review the latest developments, challenges, and ongoing research in posttransplant maintenance for acute myeloid leukemia (AML).
concept of home | Image Credit: SewcreamStudio-stock.adobe.com
June 19th 2024

HMA Therapy Translates to More Time at Home for Patients With AML

Jared Kaltwasser
People receiving hypomethylating agent (HMA) therapy spent 33 more days at home than people receiving anthracycline-based therapy in the first year after diagnosis.
conceptual image of therapy | Image Credit: ArtemisDiana-stock.adobe.com
June 13th 2024

Induction Treatment Based on Pharmacogenomics May Address Racial Disparities in AML

AJMC Contributor
Data from this new study suggest that tailoring induction therapy for acute myeloid leukemia (AML) based on cytarabine pharmacogenomic 10–single-nucleotide variant score could better treatment for these young patients, particularly those who are Black.
ALL cancer cells in blood flow | Image Credit: Laszlo-stock.adobe.com
June 5th 2024

Inotuzumab Ozogamicin Plus Dose-Adjusted EPOCH: Promise in R/R B-ALL

Gayle Turim Dickstein
Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia or lymphoma (R/R B-ALL).
Radiation word pic | Image Credit: KhengGuanToh-stock.adobe.com
May 30th 2024

Consolidative Radiotherapy a Potential Treatment for Extramedullary AML

Luke Halpern
The treatment showed effectiveness in achieving local control of acute myeloid leukemia (AML) that developed in the eyes of a pediatric patient.
ALL acute lymphoblastic leukemia | Image Credit: © sviatlana - stock.adobe.com
May 26th 2024

Ponatinib, Imatinib Face Off, but Still Room for TKI Improvement in Ph+ ALL

Gayle Turim Dickstein
Interim results of the randomized, phase 3 PhALLCON trial indicate ponatinib’s benefit over imatinib in frontline treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), but questions linger about ponatinib’s long-term safety.
Histological analysis | Image Credit: tilialucida-stock.adobe.com
May 15th 2024

Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Kimberly Rath, PharmD
Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
MRI head brain scan | Image Credit: © DedMityay - stock.adobe.com
May 7th 2024

Case Report Demonstrates Nuanced Decisions in Treating ALL Relapse With Skull Base Lesion

Jared Kaltwasser
Physicians treated the patient without surgery, although they said the patient’s case is particularly challenging and treatment was ongoing at the time of the report’s writing.
Study Shows Improvements in Posttransplant Outcomes Among Older Patients With AML
May 3rd 2024

Study Shows Improvements in Posttransplant Outcomes Among Older Patients With AML

Kimberly Rath, PharmD
Data highlight substantial improvements in outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) among older patients with acute myeloid leukemia (AML).
Older man smiling with nurse | Image Credit: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
April 17th 2024

Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate

Gayle Turim Dickstein
A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
AML| Image Credit: Dzmitry - stock.adobe.com
April 8th 2024

In AML, CAR T-Cell Therapy Has Higher CR Rate After Transplant

Jared Kaltwasser
In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
April 2nd 2024

Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia

Jordyn Sava
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
Mom and child with cancer | Image Credit: photographee.eu - stock.adobe.com
April 2nd 2024

Post Treatment, Children With ALL Experience Long-Term Fatigue

Jared Kaltwasser
This new report helps clarify the ways in which the disease—and its treatment—affects the lives of children.
Diagnosis, Treatment Remain Challenges for Chronic Disseminated Candidiasis in Acute Leukemia
March 25th 2024

Diagnosis, Treatment Remain Challenges for Chronic Disseminated Candidiasis in Acute Leukemia

Luke Halpern
A case report of a patient with acute leukemia who developed chronic disseminated candidiasis revealed difficulties in diagnosing and treating the illness.
<1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo